Cargando…

Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation

BACKGROUND: Goal Attainment Scaling (GAS) is an instrument that is intended to evaluate the effect of an intervention by assessing change in daily life activities on an individual basis. However, GAS has not been validated adequately in an RCT setting. In this paper we propose a conceptual validatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaasterland, C. M. W., van der Weide, M. C. Jansen, Roes, K. C. B., van der Lee, J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894223/
https://www.ncbi.nlm.nih.gov/pubmed/31801463
http://dx.doi.org/10.1186/s12874-019-0866-x
_version_ 1783476346068926464
author Gaasterland, C. M. W.
van der Weide, M. C. Jansen
Roes, K. C. B.
van der Lee, J. H.
author_facet Gaasterland, C. M. W.
van der Weide, M. C. Jansen
Roes, K. C. B.
van der Lee, J. H.
author_sort Gaasterland, C. M. W.
collection PubMed
description BACKGROUND: Goal Attainment Scaling (GAS) is an instrument that is intended to evaluate the effect of an intervention by assessing change in daily life activities on an individual basis. However, GAS has not been validated adequately in an RCT setting. In this paper we propose a conceptual validation plan of GAS in the setting of rare disease drug trials, and describe a hypothetical trial where GAS could be validated. METHODS: We have used the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) taxonomy to deduce which measurement properties of GAS can be evaluated, and how. As individual GAS scores cannot be interpreted outside the context of a RCT, the validation of GAS needs to be done on trial as well as on individual level. RESULTS: The procedure of GAS consists of three steps. For the step of goal selection (step 1) and definition of levels of attainment (step 2), face validity may be assessed by clinical experts. For the evaluation of the goal attainment (step 3), the inter and intra rater reliability can be evaluated on an individual level. Construct validity may be evaluated by comparison with change scores on other instruments measuring in the same domain as particular goals, if available, and by testing hypotheses about differences between groups. A difference in mean GAS scores between a group who received an efficacious intervention and a control group is an indication of well-chosen goals, and corroborates construct validity of GAS on trial level. Responsiveness of GAS cannot be evaluated due to the nature of the construct being assessed. CONCLUSION: GAS may be useful as an instrument to assess functional change as an outcome measure in heterogeneous chronic rare diseases, but it can only be interpreted and validated when used in RCTs with blinded outcome assessment. This proposed theoretical validation plan can be used as a starting point to validate GAS in specific conditions.
format Online
Article
Text
id pubmed-6894223
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68942232019-12-11 Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation Gaasterland, C. M. W. van der Weide, M. C. Jansen Roes, K. C. B. van der Lee, J. H. BMC Med Res Methodol Research Article BACKGROUND: Goal Attainment Scaling (GAS) is an instrument that is intended to evaluate the effect of an intervention by assessing change in daily life activities on an individual basis. However, GAS has not been validated adequately in an RCT setting. In this paper we propose a conceptual validation plan of GAS in the setting of rare disease drug trials, and describe a hypothetical trial where GAS could be validated. METHODS: We have used the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) taxonomy to deduce which measurement properties of GAS can be evaluated, and how. As individual GAS scores cannot be interpreted outside the context of a RCT, the validation of GAS needs to be done on trial as well as on individual level. RESULTS: The procedure of GAS consists of three steps. For the step of goal selection (step 1) and definition of levels of attainment (step 2), face validity may be assessed by clinical experts. For the evaluation of the goal attainment (step 3), the inter and intra rater reliability can be evaluated on an individual level. Construct validity may be evaluated by comparison with change scores on other instruments measuring in the same domain as particular goals, if available, and by testing hypotheses about differences between groups. A difference in mean GAS scores between a group who received an efficacious intervention and a control group is an indication of well-chosen goals, and corroborates construct validity of GAS on trial level. Responsiveness of GAS cannot be evaluated due to the nature of the construct being assessed. CONCLUSION: GAS may be useful as an instrument to assess functional change as an outcome measure in heterogeneous chronic rare diseases, but it can only be interpreted and validated when used in RCTs with blinded outcome assessment. This proposed theoretical validation plan can be used as a starting point to validate GAS in specific conditions. BioMed Central 2019-12-04 /pmc/articles/PMC6894223/ /pubmed/31801463 http://dx.doi.org/10.1186/s12874-019-0866-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gaasterland, C. M. W.
van der Weide, M. C. Jansen
Roes, K. C. B.
van der Lee, J. H.
Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
title Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
title_full Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
title_fullStr Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
title_full_unstemmed Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
title_short Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
title_sort goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894223/
https://www.ncbi.nlm.nih.gov/pubmed/31801463
http://dx.doi.org/10.1186/s12874-019-0866-x
work_keys_str_mv AT gaasterlandcmw goalattainmentscalingasanoutcomemeasureinrarediseasetrialsaconceptualproposalforvalidation
AT vanderweidemcjansen goalattainmentscalingasanoutcomemeasureinrarediseasetrialsaconceptualproposalforvalidation
AT roeskcb goalattainmentscalingasanoutcomemeasureinrarediseasetrialsaconceptualproposalforvalidation
AT vanderleejh goalattainmentscalingasanoutcomemeasureinrarediseasetrialsaconceptualproposalforvalidation